Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Puma Biotechnology, Inc.NASDAQ: PBYI

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $10.42M fell 1.3% year over year, ahead of the -9.7% change in trailing-twelve-month cost of revenue. Sequentially, it fell 54.9% from the prior quarter. Over 3 fiscal years it compounded at +1.8% a year.

Context

  • Cost of revenue amounted to 25.5% of revenue in FY2025, down 2.5 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -1.3% holds above the trailing-twelve-month pace of -9.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.42M-54.9% QoQ
Last fiscal yearDec 2025
$58.16M-9.7% YoY
LTMMar 2026
$58.03M-9.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.3%——
1 year-9.7%——
3-year CAGR+1.8%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
58.16M USD
Year-over-year change
-9.7%
4-year CAGR
-2.3%

Cost of Revenue vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.7% is the 6th highest of 8, against a peer median of +5.3%.
  • Cost of revenue amounts to 25.5% of revenue for PBYI, versus a peer median of 23.2%.
PBYI Competitors
Cost of Revenue for PBYI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PBYIPuma Biotechnology, Inc.LTM Mar 2026$58.03M USD-9.7%+1.8%25.5%
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M USD-18.4%+80.2%30.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026$11.58M USD+18.8%—2205.7%
NUVBNuvation Bio Inc.LTM Jun 2026$10.3M USD-1.0%—6.1%
VSTMVerastem, Inc.LTM Mar 2026$8.06M USD——16.3%
TNGXTango Therapeutics, Inc.LTM Sep 2026$942K USD+50.7%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$320K USD+5.3%——
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$119.31K CAD-26.6%-38.5%—
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$113K USD+31.4%——
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
NBPNovaBridge BiosciencesLTM Sep 2025CN¥0 CNY———
Peer median (excluding PBYI) —+5.3%+20.8%23.2%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue253.16M228.03M235.64M230.47M228.37M
Cost of Revenue63.7M55.09M62.68M64.4M58.16M
Gross Profit189.45M172.94M172.96M166.06M170.21M
Gross Margin74.8%75.8%73.4%72.1%74.5%
Research & Development71.87M52.24M50.38M54.94M62.07M
Selling, General & Admin116.29M89.98M89.31M80.16M71.21M
Operating Expenses188.16M149.22M140.32M135.1M132.92M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
EBITDA(4.69M)21.89M47.52M48.08M53.34M
EBITDA Margin-1.9%9.6%20.2%20.9%23.4%
Operating Income1.29M23.72M32.64M30.97M37.3M
Operating Margin0.5%10.4%13.9%13.4%16.3%
Interest Income160K813K2.61M4.72M4.08M
Interest Expense12.81M11.59M13.33M12.45M6.62M
Other Income / Expenses(30.09M)(23.26M)(9.97M)(6.87M)(1.52M)
Income Before Tax(28.8M)457K22.67M24.1M35.78M
Pre-Tax Margin-11.4%0.2%9.6%10.5%15.7%
Income Tax Expense324K455K1.08M(6.18M)4.67M
Net Income(29.13M)2K21.59M30.28M31.11M
Net Margin-11.5%0.0%9.2%13.1%13.6%
EPS (Basic)(0.72)0.020.460.620.62
EPS (Diluted)(0.72)0.020.450.620.61
Weighted Avg Shares40.64M44.67M47.13M48.65M50.01M
Weighted Avg Shares (Diluted)40.64M44.93M47.55M49.1M50.65M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.